The Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating
eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1
unselected population.
This is getting an oral presentation because of positive results.
Relatlimab got approval with a 25% increase in efficacy.
Earlier TACTI-002 results show eftilagimod doubled efficacy.
If updated results show this trend holds up we could see approval and sales within a year.
Ann: Immutep to announce new TACTI-002 data at ASCO 2022, page-15
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |